University of Zurich

University of Zurich

University of Zurich

Date Founded



Rämistraße 71,Zurich 8006

Employees (Worldwide)

5,001 - 10K

Company Description

University of Zurich is a higher education institute that offers a wide variety of Master's, Bachelor's, and Ph.D. programs. The company also specializes in the fields of clinical medicine, immunology, neuroscience, and structural biology as well as in economics. It also brings benefits to both the private and the public sectors. It makes findings from cutting-edge research available to the public in accessible and engaging lecture series and panel discussions. In addition, the University of Zurich providing a dynamic education based on critical thinking and interdisciplinary exposure. The university is committed to being an internationally significant research university, with graduate, undergraduate, and professional programs of excellent quality. University of Zurich was founded on April 29, 1833, and is headquartered in Zurich, Switzerland.

Executives & Employees


Chairman-Executive MBA Program

Director, Oncology Department

Director-Biochemistry Department

Chairman, Department of Economics




Board of Directors

Director & Partner at Niederer Kraft & Frey Ltd.

Director at University of Zurich

Honorary Senator at University of St. Gallen

Co-Founder at CT Atlantic AG

Distinguished Alumni
Iqbal Khan is now Co-President, Global Wealth Management at UBS AG
Tomislav Mihaljevic is now Chief Executive Officer & President at Cleveland Clinic
Paths to University of Zurich
Potential Connections via
Relationship Science
University of Zurich

Fluidigm Corp. is engaged in the development, manufacture and marketing of biotechnology tools fro life sciences research. It sells preparatory and analytical instruments for mass cytometry, polymerase chain reaction, library prep, single cell genomics; and consumables including integrated fluidic circuits (IFCs), assays, and reagents. The company was founded by Stephen R. Quake and Gajus V. Worthington on May 19, 1999 and is headquartered in South San Francisco, CA.

Pixium Vision SA conducts research and development on retinal implants. It develops and commercializes Bionic Vision Systems (BVS), which are implantable medical devices to treat blindness caused by degeneration of photoreceptor cells in the retina. The company was founded on Jose-Alain Sahel, Bernard Gilly, Serge Picaud, Christoph Posch, Philippe Bergonzo and Lionel Rousseau on December 28, 2011 and is headquartered in Paris, France.

Molecular Partners AG engages in the development of protein therapies for treatment of serious diseases like cancer and sight-threatening disorders. It also develops its products through its brand known as DARPins, which targets specific and potent monoclonal antibodies that offers potential to address existing limitations of antibody drugs. The company products include Abicipar, MP0250/MP0274 and Clinical Trials. Molecular Partners was founded by Christian Zahnd, Patrick Amstutz, Patrik Forrer, Andreas Plückthun and Michael Tobias Stumpp on November 22, 2004 and is headquartered in Schlieren, Switzerland.

Non-Profit Donations & Grants Received
This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by University of Zurich. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of University of Zurich's profile does not indicate a business or promotional relationship of any kind between RelSci and University of Zurich.